Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Prevalence of darunavir resistance-associated mutations: Patterns of occurrence and association with past treatment JOURNAL OF INFECTIOUS DISEASES Mitsuya, Y., Liu, T. F., Rhee, S., Fessel, W. J., Shafer, R. W. 2007; 196 (8): 1177-1179

Abstract

Eleven protease mutations have been associated with reduced susceptibility to darunavir (DRV). We examined the prevalence and covariates of these mutations in 2 populations. Thirty percent of 1175 Northern California patients and 24% of 2744 non-California patients in the Stanford HIV Drug Resistance Database had viruses with 1 or more mutations associated with resistance to DRV. In multivariate analyses, the number of DRV resistance-associated mutations depended on the number of previous protease inhibitors (PIs) administered and on amprenavir/fosamprenavir treatment. Most PI-treated patients should respond favorably to DRV-based salvage therapy.

View details for DOI 10.1086/521624

View details for Web of Science ID 000249595700010

View details for PubMedID 17955436

View details for PubMedCentralID PMC2597352